Skip to main content
OpenTrials
Completed

NCT Number: NCT06100549

Feasibility of Using Surplus qFIT Samples to Investigate the Gut Microbiota.

The Scottish Bowel Screening Programme is an enormous potential research resource; half a million people in Scotland do their bowel screening test each year. If we could obtain meaningful data on the gut microbiota in these individuals, many clinical questions could be answered using nested case-control studies relating gut microbiota profiles to cancer, obesity, cardiovascular and metabolic diseases and Alzheimer's disease. As individuals are screened from age 50 to 74 years, there would also be excellent opportunities for longer-term longitudinal studies.

Since 2017, the bowel screening programme has used qFIT testing for faecal haemoglobin. Patients collect a tiny (2 miligram) sample of their faeces into 2 mililiter of buffer but only approximately 6 microliter is required for testing. The goal of this study is to investigate whether the large number of patients' samples available from the National Bowel Screening Programme could be used in future gut microbiome studies using the leftover faeces in buffer in the qFIT tests.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Rowett Institute

Aberdeen, AB25 2ZD, United Kingdom

About this study

We aim to test the hypothesis that the 2 mg of faeces suspended in buffer reagent in the qFIT cassette will be sufficient to perform 16S rRNA gene sequencing and will yield comparable results to conventionally collected faecal samples, thus allowing us to study the large number of patients' samples available from the National Bowel Screening Programme in future studies.

If we could demonstrate that the DNA from these faeces yields similar results to that from conventionally collected specimens (e.g. 15-20 ml of faeces collected into a 30 ml stool sample pot), this could allow us to study the large number of patients' samples available from the National Bowel Screening Programme in future studies.

Other studies have investigated the potential for using fresh or frozen residual FIT test buffer instead of intact stool samples to measure faecal microbial features by 16S rRNA gene sequencing, using OC-Auto FIT cartridges (Polymedco Inc) which add 10 mg of faeces to 2 ml of buffer, but buffer stability is lower than for the EXTEL collection picker cartridges (7 days vs 32 days at room temperature; 28 days vs 120 days at 2-8oC).

We hypothesise that the small amount of faeces suspended in buffer reagent in the qFIT cassette will be sufficient to perform 16S rRNA gene sequencing and will yield comparable results to conventionally collected faecal samples.

We shall:

  • determine whether 500 ul of buffer/faeces mix from qFIT collection cassettes will yield sufficient DNA for 16S rRNA gene sequencing or whether 1.5 to 2 ml is required
  • compare 16S rRNA gene sequencing of fresh faeces from 16 human volunteers (processed within 24 hours) using qFIT cassettes and conventional faecal collection methods
  • determine the suitability of faeces collected by qFIT, held in the cassette for durations commensurate with samples handled in the Scottish Bowel Screening Programme, up to 14 days
  • quantify the DNA present in 100 qFIT samples surplus to requirements from symptomatic patients from Aberdeen Royal Infirmary, to determine the proportion of samples with adequate DNA for 16S rRNA gene sequencing.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy men and women
  • Aged 18 to 65
  • BMI 18.5 and 30 kg/m2

Exclusion criteria

  • A member of Prof Kiltie's lab
  • Cconsumed antibiotics within the last 3 months
  • Pregnant or breastfeeding
  • Cannot drop your samples off at the Rowett Institute
  • Have any of the following: History of cardiovascular disease/stroke, diabetes, gastrointestinal disease, autoimmune disorders or cancer.

Treatment and study plan

No intervention

Other

No intervention will be provided.

Primary outcomes

  1. Microbial composition using 16S sequencing.

    Time frame: 5 months

    Comparison of 16S rRNA gene sequencing of fresh faeces processed within 24 hours from 16 human volunteers using qFIT collection cassettes and conventional faecal collection methods.

Secondary outcomes

  1. DNA yield over time, quantified by Qubit

    Time frame: 6 months

    Determination of the suitability of faeces collected by qFIT based on the microbial DNA yield when held in the cassette for durations commensurate with samples handled in the Scottish Bowel Screening Programme. The extracted DNA will also be send for 16S DNA sequencing.

  2. Comparison DNA yield from 16 volunteers with NHS setting

    Time frame: 10 months

    To determine whether our carefully controlled conditions are replicated in the NHS setting, one hundred anonymised qFIT samples, held for 7-14 days post-sample analysis, will be obtained from Chemical Pathology Aberdeen Royal Infirmary under NHS Grampian Biorepository ethical approval. Extracted DNA will be quantified by Qubit (2 ul volume; can detect 0.2 ng to 100 ng) and run on an agarose gel with SYBR Safe fluorescent dye to determine the intact nature of the DNA.

Sponsors and collaborators

Lead sponsor

University of Aberdeen

Other

Collaborators

  • NHS Grampian

Registry information

Official study title

Feasibility of Using National Bowel Screening Programme Surplus qFIT Samples to Investigate the Gut Microbiota.

Acronym: FUTURISTIC

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Oct 25, 2023
Registry last updated
Feb 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.